Kelly John Alexander
Known title: Chief Financial OfficerCIK: 0001590030
Kelly John Alexander's purchase track record
How the stock did after each of Kelly John Alexander's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since March 17, 2022
Stock higher 6 months later
0%
3 months: 17%
Median 6-month return
-35.3%
3 months: -15.3%
Beat the S&P 500
0%
median -35.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/27/2024 | DTIL | $10K | +1.1% | -7.5% | +3.4% |
| 11/21/2024 | DTIL | $20K | -9.4% | -28.6% | -1.8% |
| 3/17/2023 | DTIL | $17K | -24.1% | -52.9% | +13.6% |
| 9/22/2022 | DTIL | $60K | -21.3% | -41.7% | +5.1% |
| 6/22/2022 | DTIL | $51K | -8.7% | -28.9% | +3.1% |
| 3/17/2022 | DTIL | $51K | -66.0% | -51.2% | -11.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DTIL | ▼ Sell | Open Market | 8,149 | $31K | 2/18/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 27,584 | $0 | 2/17/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 15,213 | $61K | 1/21/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 3,888 | — | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 13,900 | — | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 26,575 | — | 1/20/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 1,303 | $8K | 11/3/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 3,605 | $0 | 11/2/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 14,827 | $63K | 7/3/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 1,702 | — | 3/3/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 44,368 | — | 1/20/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 2,113 | $10K | 12/27/2024 | View on chart |
| DTIL | ▲ Buy | Open Market | 3,000 | $20K | 11/21/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 3,605 | — | 11/2/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 454 | — | 6/7/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 8,334 | $100K | 5/8/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 1,702 | — | 5/1/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 506 | $9K | 2/29/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 116,690 | — | 1/20/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 108,188 | — | 11/2/2023 | View on chart |
| DTIL | ▲ Buy | Grant | 5,951 | $2K | 8/31/2023 | View on chart |
| DTIL | ▲ Buy | Grant | 90,000 | $43K | 8/18/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 13,635 | — | 6/7/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 34,091 | — | 6/7/2023 | View on chart |
| DTIL | ▲ Buy | Open Market | 20,000 | $17K | 3/17/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 51,071 | — | 3/3/2023 | View on chart |
| DTIL | ▲ Buy | Grant | 11,605 | $11K | 2/28/2023 | View on chart |
| DTIL | ▲ Buy | Open Market | 8,200 | $10K | 9/23/2022 | View on chart |
| DTIL | ▲ Buy | Open Market | 37,037 | $50K | 9/22/2022 | View on chart |
| DTIL | ▲ Buy | Open Market | 33,784 | $51K | 6/22/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 34,090 | — | 6/7/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 13,638 | — | 6/7/2022 | View on chart |
| DTIL | ▲ Buy | Open Market | 16,677 | $51K | 3/17/2022 | View on chart |
| DTIL | ▲ Buy | Grant | 2,714 | $10K | 2/28/2022 | View on chart |
| DTIL | ▲ Buy | Grant | 998 | $11K | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.